Recent advances in Nrf2 activators, such as synthetic triterpenoids and natural compounds, highlight the need for temporal precision—activating Nrf2 early to preserve β-cell function but avoiding chronic overexpression, which may promote cancer (Mohamadi et al., 2023). This evidence concerns the gene NFE2L2 and cancer.